30 closest matches · ranked by relevance
Primary Hyperlipidemia and Mixed Dyslipidemia
Primary: Percent Change From Baseline in Low-density Lipoprotein (LDL) Apolipoprotein B-100 Fractional Catabolic Rate (FCR) — -5.07; 74.13; 83.70; 310.48 percent change — p=0.018
Type 2 Diabetes Mellitus
Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
Lipoprotein Metabolism · PCSK9 · Proteomics
Primary: Plasma PCSK9 Levels at Baseline and End of 6 Week Intervention — 13.30; 14.11; 12.44 ng/mL
Type2 Diabetes
Primary: Lipoprotein-associated Phospholipase A2 — 238.4 ng/ml
Hyperlipidemia
Primary: Apolipoprotein B48 Production Rate After Acute Oral Administration of 100mg Sitagliptin (Compared to Placebo) — 122.9; 60.6 ug/kg/day
Type 2 Diabetes
Primary: Change in Liver Fat Content — 14.8; 16.1; 10.7; 13.9 fat % — p=0.001
Non-alcoholic Fatty Liver Disease (NAFLD)
Primary: Production Rate of VLDL-1 Triacylglycerol (TAG) — 20.9; 18.9; 16.6; 12.4 grams/day — p=<0.05
Hypertriglyceridemia
Primary: HDL 15-HEPE — 3.7; 10.4 nmol/mmol phospholipid
Type 2 Diabetes Mellitus
Primary: Increased HDL-Cholesterol and Decreased Triglycerides — 7.9; 2.7; 15.7; -1.5 % Change — p=0.05
Lipid Metabolism Disorders
Primary: Cholesterol Efflux Capacity (CEC) — 1.30; 0.65 Ratio
Gestational Diabetes · Hyperlipidemia
Primary: Cholesterol — 204; 201 mg/dl
Cardiovascular Risk Factor · Lipaemia · Metabolic Disease
Primary: Postprandial Changes in Plasma Triglyceride Concentrations — 51; 90; 98 mmol/L x 360 min
Hyperlipoproteinemia Type I · Hypertriglyceridemia
Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL
Coronary Heart Disease
Primary: Cholesteryl Ester Fractional Clearance Rate
Hyperlipidemia
Primary: Myocardial Perfusion at Rest — 55; 135 IU/s
Refractory Angina · Raised Lipoprotein(a)>50mg/dL or >500mg/L
Primary: Changes in Quantitative Myocardial Perfusion Measured by Stress/Rest Cardiovascular Magnetic Resonance Imaging — 0.47; -0.16 ratio — p=0.001
Atherosclerosis · Low-density Lipoproteins Aggregation Susceptibility · Low-density Lipoprotein Lipid Composition
Primary: LDL Aggregation Susceptibility — 111.3; 113.1 Minutes
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus · Hypercholesterolemia
Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L
Metabolic Syndrome
Primary: L5 Concentration in Metabolic Syndrome Patients — 35.97; 17.8233; 29.736; 23.1 mg/dL
Dyslipidemias
Primary: Rate of Appearance of 3H Cholesterol in the Total HDL Fraction Before and After 12 Weeks of Treatment With Niacin — 3.24; 4.16; 2.61; 3.72 %/mol/h — p=0.8
Type 2 Diabetes · Dyslipidemia
Primary: Hepatic Fatty Acid Oxidation — 0.052; 0.045; 0.042 micromol/ml/min
Familial Partial Lipodystrophy
Primary: Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27) — -59.9 percent change
Dyslipidemia
Primary: Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin…
Hyperlipidemia · Insulin Resistance · Type 2 Diabetes
Primary: Steady-state Plasma Glucose (SSPG) — 130; 139 mg/dL — p=0.01
Metabolic Syndrome
Primary: Mean Low Density Lipoprotein Cholesterol in Blood — 70; 135 mg/dl
HIV Infections
Primary: Effect of Drug Regimens on Serum Triglycerides. — 228.0; 230.4; 293.4; 290.0 mg/dL — p=0.94
Metabolic Syndrome
Primary: Change in Hepatic Lipogenesis — 5.6 abs percent change fasting lipogenesis
Cardiovascular Disease
Primary: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) — 5; 3; 3; 5 Participants
Metabolic Syndrome
Primary: Basal HDL-cholesterol Level — 39.5 mg/dL